For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Alnylam Pharmaceuticals, Inc.

USPTO Granted Patents = 444

CIPO Patents = 26

EPO Patents = 112

Trademarks = 38

Forward Citations = 5,300

Loading Chart...

Loading Chart...

219 inventors (with patents filed for the assignee):

Muthiah Manoharan (165 out of 323 patents)

Kallanthottathil G Rajeev (156 out of 193 patents)

Martin A Maier (111 out of 127 patents)

4. Kevin Fitzgerald (78 out of 80 patents)

5. Brian R Bettencourt (73 out of 79 patents)

6. Gregory Hinkle (71 out of 96 patents)

7. Stuart Milstein (67 out of 91 patents)

8. Akin Akinc (50 out of 60 patents)

9. Pamela Tan (45 out of 55 patents)

10. Klaus Charisse (42 out of 42 patents)

11. Hans-Peter Vornlocher (39 out of 53 patents)

12. Vasant R Jadhav (36 out of 46 patents)

13. William Querbes (35 out of 35 patents)

14. Jayaprakash K Nair (34 out of 41 patents)

15. Shigeo Matsuda (31 out of 31 patents)

Core Competencies:

iRNA Compositions

Biodegradable Lipids

Modified RNA Agents

Oligonucleotide-Ligand Conjugates

Extrahepatic Delivery

Transthyretin

Coagulation Factors

Huntingtin

Coronaviruses

Carbohydrate Conjugates

Modified Double-Stranded RNA

Factor XII

444 patents: Sort by Forward Citations

1. 12492401 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2025-12-09),

2. 12486512 - Solute carrier family member iRNA compositions and methods of use thereof (2025-12-02),

3. 12480125 - Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof (2025-11-25),

4. 12473550 - Coagulation factor V (F5) iRNA compositions and methods of use thereof (2025-11-18),

5. 12467051 - Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof (2025-11-11),

6. 12460206 - PCSK9 iRNA compositions and methods of use thereof (2025-11-04),

7. 12416006 - Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof (2025-09-16),

8. 12404508 - Ketohexokinase (KHK) iRNA compositions and methods of use thereof (2025-09-02),

9. 12397013 - Extrahepatic delivery (2025-08-26),

10. 12391945 - Coronavirus IRNA compositions and methods of use thereof (2025-08-19),

11. 12385044 - Modified double-stranded RNA agents (2025-08-12),

12. 12385043 - Modified double-stranded RNA agents (2025-08-12),

13. 12378553 - Modified double-stranded RNA agents (2025-08-05),

14. 12365896 - Complement component C3 iRNA compositions and methods of use thereof (2025-07-22),

15. 12364762 - Biodegradable lipids for the delivery of active agents (2025-07-22),

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing RNA interference (RNAi) therapies for a wide range of diseases. Using its proprietary RNAi technology, the company aims to silence or inhibit the expression of specific genes known to cause diseases. Alnylam's innovative approach has the potential to revolutionize the treatment of various genetic and rare diseases. For more information, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

444 Patents

#8 in Cambridge, MA

#61 in Massachusetts

#1,037 in US

#2,074 in the World

Cambridge, MA, United States of America

Alnylam Pharmaceuticals, Inc.

Forward Citations = 5,300

219 inventors:

Muthiah Manoharan (165 out of 323 patents)

Kallanthottathil G Rajeev (156 out of 193 patents)

Martin A Maier (111 out of 127 patents)

4. Kevin Fitzgerald (78 out of 80 patents)

5. Brian R Bettencourt (73 out of 79 patents)

Please report any incorrect information to support@idiyas.com

Loading…